Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704
A new three-drug chemotherapy combination before surgery nearly doubled three-year survival in advanced gastric cancer patients.
JCOG1704 3-year follow-up confirms preoperative DOS chemotherapy for gastric cancer with extensive lymph node metastasis achieves an unprecedented 86.7% 3-year OS versus 58.8% with the prior cisplatin+S-1 standard. These durable outcomes led the JCOG community to declare DOS a provisional standard of care for this setting without requiring a Phase III trial.
What the study was
- Study design
- Phase II trial (3-year follow-up)
- Population
- HER2-negative gastric cancer with bulky nodal and/or para-aortic node metastasis; n=47
- Sample size
- 47
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Gastric Cancer
Why it surfaced
3-year follow-up Phase II data showing 86.7% OS for gastric cancer with para-aortic/bulky nodal disease — dramatically exceeds prior standard and has been provisionally adopted as standard of care in Japan; important for precision oncology and treatment decision-making.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.